title: Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
authors.forename: P
authors.initials: P
authors.lastname: Osin
authors.forename: T
authors.initials: T
authors.lastname: Crook
authors.forename: T
authors.initials: T
authors.lastname: Powles
authors.forename: J
authors.initials: J
authors.lastname: Peto
authors.forename: B
authors.initials: B
authors.lastname: Gusterson
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D019398:Genes, BRCA1 / Q000235:genetics*; D006801:Humans; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen